Title page

Original article

Paper title

Author1[a], Author2[b], Author3[a,*], Author4[b,*]

[a]*Affiliation 1, Address, City and Postal Code, Country*

[b]*Affiliation 2, Address, City and Postal Code, Country*

*Corresponding author(s). Tel.: +86 ** ********; fax: +86 ** ********.

E-mail address(es): Author3@affiliation1 (Author1), Author4@affiliation2 (Author2).

Acknowledgments

This study was supported by Foundation A (No. ***, Country), Foundation B (No. ***, Country), and Foundation C (No. ***, Country). The author would like to thank Dr. *** (Affiliation, City, Country).

Author contributions

(Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure. Full author names should be used.)

Conflicts of interest

(Example: The authors declare no conflicts of interest.)

Graphical abstract

Please insert or paste the graph here.

(It is better a color image with high resolution (dpi > 300) which clearly represents the work described in the article.)

Please provide a short abstract (one or two sentences, less than 30 words).

(It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online.)

(Author names and affiliations should not be included in this part when submitting your papers.)

Manuscript (without author details)

Original article

Paper title

Abstract Type your Abstract text here (less than 200 words).

(A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the methods applied, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.)

KEY WORDS Keyword_1; Keyword_2; Keyword_3; Keyword_4

(Please provide 8 keywords.)

Running title: (Less than 10 words.)

The main text of the article should appear here and should be subdivided in the simplest possible way consistent with clarity. Ensure that all tables, figures, and schemes are cited in the text in numerical order. The preferred position for chemical structures should be indicated. Trade names should have an initial capital letter. All measurements and data should be given in SI units where possible, or in other internationally accepted units. Abbreviations should be defined on first usage, and used consistently throughout the text.

Headings and subheadings should be used as shown. All sections only hold essential information; others can be put in Supporting information files.

1. Introduction

2. Materials and methods

For devices, equipment, and reagents, nonproprietary names or descriptive phrasing is preferred to proprietary names. When proprietary names are used, all equipment, device, and reagent names should be capitalized in accordance with the manufacturer's use. No trademark symbols are needed. At first mention in the article text, the name of the manufacturer (City, State, Country) should follow in parentheses. The best way to verify spelling is to check the manufacturer's website.

For example:

> The isolated RNA was treated with DNase using the Qiagen RNase-Free DNase Kit and RNeasy Spin Columns (Qiagen, City, Country) and dissolved in RNase-free water. RNA quality was checked using the Agilent 2100 Bioanalyzer (Agilent Technologies, City, Country).

2.1. Reagents

2.2. Studies in humans and animals

For studies in humans and animals, ethics statement should be included. See details in https://www.elsevier.com/journals/acta-pharmaceutica-sinica-b/2211-3835/guide-for-authors.

3. Results

4. Discussion

(or Results and discussion)

5. Conclusions

For papers on directions of medicinal chemistry and natural products:

1. Introduction

2. Results

3. Discussion

(or Results and discussion)

4. Conclusions

5. Experimental

5.1. Reagents

5.2. Animals

Graphics, including tables, will be located at the top or bottom of the column following their first citation in the text during production (unless they are equations, which appear in the flow of the text). They can be single column (⩽8.5 cm) or double columns (⩽16 cm) as appropriate and require appropriate captions. All characters should be uniform in Times New Roman or Arial.

References cited in tables, figures, or boxes should be cited in sequence with references in the text (*e.g.*, if Table 2 contains a previously uncited reference, it should be given the number following the last-cited reference in the text before the callout for Table 2).

See following samples:



Figure 1 Figure captions. (A) is ; (B) indicates ; (C) is ; (D) shows. Data are mean ± SD, n=5; $^{*}P$<0.05, $^{**}P$<0.01 and $^{***}P$<0.001 *vs.* Control/Model. ns, not significant. Scale bar = 50 μm.



Figure 2 Figure captions. (A) is ; (B) indicates ; (C) is ; (D) shows ; (E)–(G) are . Data are mean ± SD, n=5; $^{*}P$<0.05, $^{**}P$<0.01 and $^{***}P$<0.001 *vs*. Control/Model. ns, not significant. Scale bar = 50 μm.

Table 1 Electrochemical and absorption and emission data[a].

Compd.	$E_{1/2,anodic}$ (V)	$E_{1/2,cathodic}$ (V)	$\lambda_{max,abs}$ (nm) ($\varepsilon/10^5$ L/mol·cm)	$\lambda_{max,emi}$ (nm)	Φ[b]
1	+1.02	–	288 (0.28), 355 (0.28)	458	98.1%
2$(PF_6)_2$	+1.05	ND	290 (0.61), 466 (0.20)	606	16.7%
2$(PF_6)_2$ (in CH_3CN)	+1.07,+1.36	−1.32, −1.50,−1.75	ND	ND	ND
3	+0.80,+1.10	–	285 (0.33), 372 (0.53)	504	4.0%
4$(PF_6)_4$	+0.89,+1.09	ND	289 (1.22), 468 (0.39)	606	<1%
4$(PF_6)_4$ (in CH_3CN)	+0.94, +1.02, +1.38	−1.29	ND	ND	ND

[a]Measurements were performed in CH_2Cl_2 unless otherwise noted. Potential is reported as the $E_{1/2}$ value *vs*. Ag/AgCl. The excitation wavelength is 350 nm for **1** and **3** and 460 nm for **2**$(PF_6)_2$ and **4**$(PF_6)_4$, respectively.

[b]Absolute quantum yield.

–not applicable.

ND, not detected.

References

Please ensure that each reference cited in the text is also present in the reference list and indicate references by number(s) in line with the text (including the tables and figures). Formatting for the common references is shown below:

Reference to a journal publication

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2000;**163**:51–9.

Reference to a book:

2. Strunk W Jr, White EB. *The elements of style*. 3rd ed. New York: Macmillan; 1979.

Reference to a chapter in an edited book:

3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*. New York: E-Publishing Inc.; 1999. p. 281–304.

Reference to a patent:

Inventors; assignee. Title. United States patent US No. Year Month Day.

Reference to a website:

Author (or, if no author is available, the name of the organization responsible for the site). Title (or, if no title is available, the name of the organization responsible for the site). Name of the website. Published [date]. Updated [date]. Accessed [date]. URL.

As a minimum, the full URL should be given. Any further information, if known (author names, dates, reference to a source publication, *etc.*), should also be given. Web references should be included in the reference list.

Supporting Information

Supporting Tables and Figures should be provided in this section.

For papers on directions of medicinal chemistry and natural products, structural identification spectra (NMR & HRMS) need to be provided in this section.

Table S1

Table S2

Figure S1

Figure S2

Figure S3

(Author names and affiliations should not be included in this part when submitting your papers.)